17.07
5.57%
0.90
시간 외 거래:
17.33
0.26
+1.52%
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Yahoo Finance
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | ARCT Stock News - StockTitan
Sumitomo Mitsui Trust Group Inc. Buys 712,650 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Avian Flu: FDA Authorizes Self-Replicating Vaccine Trial to Bill Gates-Backed Company, "Study Can Proceed" - presskit.it
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data (NASDAQ:ARCT) - Seeking Alpha
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan
Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate - BioWorld Online
Possible Signal As Arcturus Therapeutics Holdings Insiders Sell US$1.6m In Stock - Simply Wall St
Another Avian Influenza mRNA Vaccine Candidate Advances - Precision Vaccinations
Arcturus Gets FDA Green Light for H5N1 Flu mRNA Vaccine Trial, Backed by BARDA | ARCT Stock News - StockTitan
What is HC Wainwright's Estimate for ARCT FY2028 Earnings? - MarketBeat
Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright - Defense World
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Business Wire
Earnings call: Arcturus Therapeutics reported a net loss of $6.9 million - Investing.com Australia
Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus.com
Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance UK
Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones - TipRanks
Arcturus Therapeutics Holdings Inc earnings beat by $0.31, revenue fell short of estimates - Investing.com
ARCTArcturus Therapeutics Holdings Inc. Latest Stock News & Market Updates - StockTitan
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcturus Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - Business Wire
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Repor - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Sumitomo Mitsui Trust Group, Inc. Expands Investment in Arcturus Therapeutics Holdings Inc. - GuruFocus.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Empire Life Investments Inc. Purchases New Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (ARCT) Scheduled to Post Earnings on Thursday - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 - Business Wire
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy - MSN
Leerink Partners Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Outperform Recommendation - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 6.1%What's Next? - MarketBeat
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
8,235 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Acquired by SG Americas Securities LLC - Defense World
A slow start for self-amplifying mRNA vaccines - Yahoo Finance
Vontobel Holding Ltd. Trims Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 5.8% Following Insider Selling - MarketBeat
AQR Capital Management LLC Has $285,000 Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Insider Sale at Arcturus Therapeutics Holdings Inc (ARCT) - GuruFocus.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula Sells 12,000 Shares - MarketBeat
Arcturus Therapeutics executive sells $249,121 in stock By Investing.com - Investing.com Canada
Arcturus Therapeutics executive sells $249,121 in stock - Investing.com India
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Update - MarketBeat
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way - GlobeNewswire Inc.
자본화:
|
볼륨(24시간):